Loading...
Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Loading...
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Thapsia garganica
North African and Mediterranean Apiaceae with extremely irritating resin historically used for rubefacient effects.
Thapsia garganica is a highly toxic Mediterranean Apiaceae historically used as a topical rubefacient for rheumatism. Modern research focuses on its active compound thapsigargin, a potent SERCA pump inhibitor under investigation for cancer therapy. The plant contains daucane sesquiterpenes responsible for its severe irritant and blistering effects.
Thapsigargin irreversibly inhibits sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to cytosolic calcium increase, ER stress, and apoptosis. This mechanism is exploited in targeted cancer therapies, such as the prodrug mipsagargin. Topical application causes severe inflammation and blistering via direct cytotoxicity and activation of inflammatory pathways, including prostaglandin release.
North African and Mediterranean Apiaceae with extremely irritating resin historically used for rubefacient effects.
Thapsia garganica is a highly toxic Mediterranean Apiaceae historically used as a topical rubefacient for rheumatism. Modern research focuses on its active compound thapsigargin, a potent SERCA pump inhibitor under investigation for cancer therapy. The plant contains daucane sesquiterpenes responsible for its severe irritant and blistering effects.
Thapsigargin irreversibly inhibits sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to cytosolic calcium increase, ER stress, and apoptosis. This mechanism is exploited in targeted cancer therapies, such as the prodrug mipsagargin. Topical application causes severe inflammation and blistering via direct cytotoxicity and activation of inflammatory pathways, including prostaglandin release.